SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds
February 22, 2023 08:00 ET
|
SciSparc Ltd
Tel Aviv, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of...
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
February 22, 2023 08:00 ET
|
Clearmind Medicine Inc.
The company submitted three provisional patent applications with the United States Patent and Trademark Office to protect the novel combination compounds with SciSparc's PEA Tel Aviv, Israel /...
SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy
December 07, 2022 08:40 ET
|
SciSparc Ltd
The non- clinical study was conducted at The Chaim Sheba Medical Center in Israel Tel-Aviv, Dec. 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage...